Results 1 to 10 of about 9,761 (227)

Real world evidence (RWE) - Are we (RWE) ready?

Perspectives in Clinical Research, 2018
Real world evidence is important as it complements data from randomised controlled trials (RCTs). Both have limitations in design, interpretation, and extrapolatability.
Viraj Ramesh Suvarna
exaly   +5 more sources

AMA- and RWE- Based Adaptive Kalman Filter for Denoising Fiber Optic Gyroscope Drift Signal

Sensors, 2015
An improved double-factor adaptive Kalman filter called AMA-RWE-DFAKF is proposed to denoise fiber optic gyroscope (FOG) drift signal in both static and dynamic conditions.
Gongliu Yang
exaly   +3 more sources

RWE Framework: An Interactive Visual Tool to Support a Real-World Evidence Study Design

Drugs - Real World Outcomes, 2019
Objectives Real-world evidence (RWE) is essential for the development of pharmaceutical and medical technologies and informs treatment-related decisions by regulatory agencies, payers, healthcare providers, and patients.
Andrew Xia, Caroline Schaefer, Matthew Hirst   +2 more
exaly   +3 more sources

Use of Real-World Evidence in Health Technology Assessments of Non-Oncology Rare Disease Therapies [PDF]

Journal of Market Access & Health Policy
Background: Real-world evidence (RWE) can complement clinical trials to inform health technology assessments (HTAs). This study examined the extent to which RWE is considered in HTAs of non-oncology orphan medicinal products across six agencies globally.
Oliver Blandy, Pierluigi Lembo, Rebecca Folorunso, Karl-Johan Myren, Helene Chevrou-Severac, Simu K. Thomas   +5 more
doaj   +2 more sources

Mapping the Use of Real-World Evidence Across the EU Health Technology Assessment Regulation: Methodological Considerations, Challenges, and Opportunities for Harmonization [PDF]

Journal of Market Access & Health Policy
Methodological guidelines for real-world evidence (RWE) in European Union (EU) joint clinical assessments (JCA) are lacking. This manuscript explores RWE potential in EU health technology assessment (HTA) and offers recommendations for generating high ...
Grammati Sarri, Bengt Liljas, Keith R. Abrams, Stephen J. Duffield, Murtuza Bharmal   +4 more
doaj   +2 more sources

R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 27 [PDF]

Journal of Comparative Effectiveness Research
In this update, we review the US FDA’s updated compendium of real-world evidence (RWE) use in medical device regulatory decisions, a comprehensive scan of RWE utilization in Canadian drug reimbursement submissions, and Institute for Clinical and ...
Paul Arora, Sreeram V Ramagopalan
doaj   +2 more sources

The burden of hospitalisations for COVID-19 in France: a study of all cases in the national insurance claims database in 2020

Journal of Market Access & Health Policy, 2023
Background The economic consequences of the recent COVID-19 pandemic were substantial. However, direct medical costs in France have not been determined.Objective To describe patient characteristics, intensity of care, mortality, and direct medical costs ...
Claire Leboucher, Cécile Blein, Valérie Machuron, Kelly Benyounes, Katell Le lay, Aurélie Millier, Romain Supiot, François Raffi   +7 more
doaj   +1 more source

Health Canada Usage of Real World Evidence (RWE) in Regulatory Decision Making compared with FDA/EMA usage based on publicly available information

Journal of Pharmacy & Pharmaceutical Sciences, 2022
Purpose: Between January 2020 and December 2021, Health Canada provided a Summary Basis of Decision (SBD) for each of 110 products approved, including 29 oncology products and 21 non-oncology orphan drugs.
Catherine Lau, Fakhreddin Jamali, Raimar Loebenberg   +2 more
doaj   +1 more source

How can real‐world evidence aid decision making during the life cycle of nonprescription medicines?

Clinical and Translational Science, 2022
Real‐world evidence (RWE) is an emerging scientific discipline which is being increasingly utilized for decision making on prescription‐only medicines.
Emese Csoke, Sabine Landes, Matthew J. Francis, Larry Ma, Denise Teotico Pohlhaus, Christelle Anquez‐Traxler   +5 more
doaj   +1 more source

An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER)

Journal of Market Access & Health Policy, 2021
Background: Recent cost-utility analysis (CUA) models for onasemnogene abeparvovec (Zolgensma®, formerly AVXS-101) in spinal muscular atrophy type 1 (SMA1) differ on key assumptions and results.
Rebecca Dean, Ivar Jensen, Phil Cyr, Beckley Miller, Benit Maru, Douglas M. Sproule, Douglas E. Feltner, Thomas Wiesner, Daniel C. Malone, Matthias Bischof, Walter Toro, Omar Dabbous   +11 more
doaj   +1 more source